Merck KGaA (FRA:MRK) has been given an average recommendation of “Hold” by the twenty-three brokerages that are covering the firm, MarketBeat.com reports. Twelve research analysts have rated the stock with a hold rating and eleven have issued a buy rating on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is €102.25 ($126.23).
Several equities research analysts recently commented on MRK shares. JPMorgan Chase & Co. set a €95.00 ($117.28) target price on Merck KGaA and gave the company a “neutral” rating in a research report on Friday, December 29th. DZ Bank restated a “buy” rating on shares of Merck KGaA in a research report on Monday, February 12th. UBS Group set a €120.00 ($148.15) target price on Merck KGaA and gave the company a “buy” rating in a research report on Friday, February 16th. Nord/LB restated a “neutral” rating on shares of Merck KGaA in a research report on Tuesday, January 2nd. Finally, Societe Generale set a €88.00 ($108.64) target price on Merck KGaA and gave the company a “neutral” rating in a research report on Friday, March 9th.
Shares of Merck KGaA (FRA:MRK) traded down €0.26 ($0.32) during trading on Friday, hitting €78.08 ($96.40). The company had a trading volume of 492,340 shares. Merck KGaA has a 52 week low of €76.60 ($94.57) and a 52 week high of €115.00 ($141.98). The company has a market cap of $10,040.00 and a price-to-earnings ratio of 13.06.
ILLEGAL ACTIVITY WARNING: This article was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/07/merck-kgaa-mrk-receives-average-recommendation-of-hold-from-analysts.html.
About Merck KGaA
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.